argenx $ARGX
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS29
PHASE 3 / 2-316
RECRUITING11
READOUTS ≤12 MONTHS11
READOUT SLIPPED >6 MO53%
Delay Index: of 19 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +6.4 months). See all sponsors →
Open argenx on the live radar map → 📅 $ARGX readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ADAPT SERON NCT06298552 |
P3 | Active, not recruiting | Generalized Myasthenia Gravis; gMG | 119 | 2025-06-30 |
| VARVARA NCT05907096 |
P2 | Active, not recruiting | Delayed Graft Function | 103 | 2025-10-16 (-5 mo) |
| ADAPT oculus NCT06558279 |
P3 | Active, not recruiting | Myasthenia Gravis, Ocular | 141 | 2026-01-12 (+1 mo) |
| Empassion NCT06742190 |
P3 | Active, not recruiting | Multifocal Motor Neuropathy (MMN); MMN | 154 | 2026-09 |
| empacific NCT06284954 |
P2 | Active, not recruiting | Dermatomyositis; Myositis | 3 | 2026-11 (+15 mo) |
| ADAPT Jr NCT04833894 |
P2/3 | Active, not recruiting | Generalized Myasthenia Gravis | 15 | 2027-03 (+28 mo) |
| eSScape NCT06655155 |
P2 | Active, not recruiting | Systemic Sclerosis (SSc) | 87 | 2027-03 (+6 mo) |
| ADHERE+ NCT04280718 |
P2 | Active, not recruiting | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 229 | 2027-04-30 (+35 mo) |
| Unity NCT06684847 |
P3 | Active, not recruiting | Primary Sjogrens Disease | 631 | 2027-07 |
| emvigorate NCT06920004 |
P3 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy; CIDP | 218 | 2027-09 (+4 mo) |
| ADAPT Jr SC NCT06392386 |
P2/3 | Recruiting | Generalized Myasthenia Gravis | 12 | 2027-09 (+11 mo) |
| ADVANCE SC+ NCT04812925 |
P3 | Active, not recruiting | Primary Immune Thrombocytopenia | 173 | 2027-10 (+12 mo) |
| ADAPT Forward2 NCT07673627 |
P2 | Recruiting | AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis (MG) | 40 | 2027-10 |
| emnergize NCT07091630 |
P3 | Recruiting | Chronic Inflammatory Demyelinating Polyneuropathy; CIDP | 160 | 2027-10-07 |
| Shamrock NCT06503731 |
P2 | Active, not recruiting | Antibody-mediated Rejection | 33 | 2027-11 (+2 mo) |
| embridge NCT07821762 |
P2 | Not yet recruiting | Guillain-Barré Syndrome (GBS) | 63 | 2028-01 |
| Efgartigimod IV NCT07284420 |
P2 | Recruiting | AChR-Ab Seropositive Generalized Myasthenia Gravis; Myasthenia Gravis | 70 | 2028-03-07 |
| advance NEXT NCT06544499 |
P3 | Recruiting | Primary Immune Thrombocytopenia (ITP) | 69 | 2028-06 |
| VitaliThy NCT07596849 |
P3 | Recruiting | Graves Disease | 230 | 2028-06 |
| VitaliThy NCT07570316 |
P3 | Recruiting | Graves' Disease; Graves Disease | 230 | 2028-06 |
| SERENITY NCT07760818 |
P2 | Not yet recruiting | Sjogrens Disease; Primary Sjögren's Syndrome Painful Sensory Neuropathies | 75 | 2028-07-28 |
| ALKIVIA+ NCT05979441 |
P3 | Enrolling by invitation | Myositis; Active Idiopathic Inflammatory Myopathy | 240 | 2028-09 (+12 mo) |
| Advance Jr NCT07194850 |
P2/3 | Recruiting | Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia | 24 | 2028-10 (+7 mo) |
| Sparkle NCT07287982 |
P2 | Recruiting | Spinal Muscular Atrophy (SMA) | 60 | 2029-05-28 |
| ADAPT Jr + NCT05374590 |
P2/3 | Enrolling by invitation | Generalized Myasthenia Gravis; gMG | 12 | 2029-09 (+40 mo) |
| ARDA+ NCT05405361 |
P2 | Active, not recruiting | Multifocal Motor Neuropathy (MMN) | 51 | 2029-09-30 (+47 mo) |
| Verdant NCT07773727 |
P2 | Recruiting | Immunoglobulin A Nephropathy (IgAN) | 120 | 2029-10-29 |
| Polaris NCT07583641 |
P2 | Not yet recruiting | Autoimmune Encephalitis (AE) | 170 | 2030-07 |
| CoMetS NCT07746089 |
P3 | Not yet recruiting | Congenital Myasthenic Syndrome; CMS | 105 | 2030-10 |